Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $33.00

Keros Therapeutics, Inc. (NASDAQ:KROS) gapped up before the market opened on Monday . The stock had previously closed at $33.00, but opened at $34.87. Keros Therapeutics shares last traded at $38.45, with a volume of 13,586 shares trading hands.

KROS has been the subject of several research reports. Jefferies Financial Group restated a “buy” rating and set a $70.00 price objective on shares of Keros Therapeutics in a research note on Wednesday, June 23rd. Piper Sandler decreased their target price on shares of Keros Therapeutics from $95.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Monday, August 9th. SVB Leerink reiterated a “buy” rating on shares of Keros Therapeutics in a research note on Sunday, June 27th. Finally, Zacks Investment Research upgraded shares of Keros Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $85.00.

The firm has a market cap of $954.76 million, a PE ratio of -13.52 and a beta of 2.60. The stock’s fifty day moving average price is $33.97 and its 200-day moving average price is $46.49.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Thursday, August 5th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.01). The firm had revenue of $0.10 million for the quarter. As a group, sell-side analysts predict that Keros Therapeutics, Inc. will post -2.89 EPS for the current year.

In related news, Director Julius Knowles sold 23,834 shares of the company’s stock in a transaction dated Thursday, July 1st. The shares were sold at an average price of $41.28, for a total value of $983,867.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 36.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System lifted its position in shares of Keros Therapeutics by 1.0% during the first quarter. California State Teachers Retirement System now owns 19,931 shares of the company’s stock worth $1,227,000 after purchasing an additional 207 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in Keros Therapeutics by 10.3% in the second quarter. Virtus ETF Advisers LLC now owns 4,229 shares of the company’s stock valued at $180,000 after acquiring an additional 394 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Keros Therapeutics by 9.5% in the first quarter. JPMorgan Chase & Co. now owns 6,389 shares of the company’s stock valued at $393,000 after acquiring an additional 555 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Keros Therapeutics by 7.2% in the first quarter. New York State Common Retirement Fund now owns 11,900 shares of the company’s stock valued at $732,000 after acquiring an additional 800 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Keros Therapeutics in the first quarter valued at approximately $50,000. 60.48% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile (NASDAQ:KROS)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.